{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T05:18:21Z","timestamp":1738300701886,"version":"3.35.0"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>The aim of this study was to determine the prevalence of advanced hepatic fibrosis and to individualize using Bayesian analysis its associated risk factors in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) being cared for in three Alsatian cardio-metabolic health networks in the North East of France. Overall, 712 patients aged \u226518 years with a female predominance were included into a prospective, cross-sectional, and observational study. Advanced fibrosis and severe steatosis were evaluated using transient elastography (FibroScan<jats:sup>\u00ae<\/jats:sup>). The proportion of MASLD patients was 80% and 84% in women and men (difference -4.2% [-10.0; 1.9]), respectively. Advanced fibrosis was observed in 11% of patients, being more common in men (16.9%) than women (7.5%) (difference 9.4 [4.3\u201315.0]). Severe steatosis was also more common in men (74.9%) than women (63.4%) (difference 11.4 [4.2\u201318.2]). Only three of the tested variables were likely associated with advanced fibrosis: gender (OR: 1.78 [1.17\u20132.68]; Pr [OR &gt;1] = 1), T2DM (OR: 1.54 [1\u20132.37]; Pr [OR &gt;1] = 0.97) and hypertriglyceridemia (OR: 1.49 [0.97\u20132.27]; Pr (OR &gt;1) = 0.97). In conclusion, this study confirmed the usefulness of assessing hepatic fibrosis in patients with metabolic dysfunction. Therefore, access to FibroScan<jats:sup>\u00ae<\/jats:sup> should be facilitated in all cardio-metabolic health networks.<\/jats:p>","DOI":"10.1371\/journal.pone.0316158","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T18:26:28Z","timestamp":1738261588000},"page":"e0316158","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of advanced hepatic fibrosis and individualization of associated risk factors by Bayesian analysis in MASLD patients in French cardio-metabolic health networks"],"prefix":"10.1371","volume":"20","author":[{"given":"Michel","family":"Doffoel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2113-2857","authenticated-orcid":true,"given":"Fr\u00e9d\u00e9ric","family":"Chaffraix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archia","family":"Chahard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Gras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Odile","family":"Bonomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Bildstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Tripon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maude","family":"Royant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"issue":"3","key":"pone.0316158.ref001","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"issue":"2","key":"pone.0316158.ref002","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jhep.2023.03.040","article-title":"Global incidence of non-alcoholic fatty liver disease: a systematic review and meta-analysis of 63 studies and 1,201,807 persons","volume":"79","author":"MH Le","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"pone.0316158.ref003","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1053\/j.gastro.2020.04.048","article-title":"Prevalence and risk factors of nonalcoholic fatty liver disease and advanced fibrosis in general population: the French nationwide NASH-CO study","volume":"159","author":"O Nabi","year":"2020","journal-title":"Gastroenterology"},{"issue":"6","key":"pone.0316158.ref004","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"H Hagstrom","year":"2017","journal-title":"J Hepatol"},{"issue":"6","key":"pone.0316158.ref005","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/liv.14828","article-title":"Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population","volume":"41","author":"S Ciardullo","year":"2021","journal-title":"Liver Int"},{"issue":"5","key":"pone.0316158.ref006","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"L Castera","year":"2019","journal-title":"Gastroenterology"},{"issue":"2","key":"pone.0316158.ref007","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jhep.2019.04.020","article-title":"New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD","volume":"71","author":"J Boursier","year":"2019","journal-title":"J Hepatol"},{"issue":"4","key":"pone.0316158.ref008","doi-asserted-by":"crossref","first-page":"e1003100","DOI":"10.1371\/journal.pmed.1003100","article-title":"Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies","volume":"17","author":"H Jarvis","year":"2020","journal-title":"PLoS Med"},{"issue":"2","key":"pone.0316158.ref009","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/apt.14411","article-title":"Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration","volume":"47","author":"YA Patel","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"pone.0316158.ref010","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s10620-019-05986-9","article-title":"Impact of NAFLD on the incidence of cardiovascular diseases in a primary care population in Germany","volume":"65","author":"C Labenz","year":"2020","journal-title":"Dig Dis Sci"},{"key":"pone.0316158.ref011","doi-asserted-by":"crossref","first-page":"56","DOI":"10.12688\/f1000research.21918.1","article-title":"Dyslipidemia as a risk factor for liver fibrosis progression in a multicentric population with non-alcoholic steatohepatitis","volume":"9","author":"N Mendez-Sanchez","year":"2020","journal-title":"F 1000Research"},{"issue":"1","key":"pone.0316158.ref012","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12876-020-01240-z","article-title":"Predictors of advanced fibrosis in elderly patients with biopsy-confirmed nonalcoholic fatty liver disease: the GOASIA study","volume":"20","author":"P Pitisuttithum","year":"2020","journal-title":"BMC Gastroenterol"},{"key":"pone.0316158.ref013","first-page":"5","article-title":"Association between smoking and liver fibrosis among patients with nonalcoholic fatty liver disease","author":"H Ou","year":"2019","journal-title":"Canadian J Gastroenterol Hepatol"},{"issue":"8","key":"pone.0316158.ref014","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/apt.17388","article-title":"Meta-analysis: the impact of light-to-moderate alcohol consumption on progressive non-alcoholic fatty liver disease","volume":"57","author":"L Magherman","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"pone.0316158.ref015","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2337\/dc20-1778","article-title":"High prevalence of advanced liver fibrosis assessed by transient elastography among U.S. adults with type 2 diabetes","volume":"44","author":"S Ciardullo","year":"2021","journal-title":"Diabetes Care"},{"issue":"4","key":"pone.0316158.ref016","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"M Romero-Gomez","year":"2017","journal-title":"J Hepatol"},{"issue":"6","key":"pone.0316158.ref017","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/hep.23535","article-title":"Increased fructose consumption is associated with fibrosis severity in patients with NAFLD","volume":"51","author":"MF Abdelmalek","year":"2010","journal-title":"Hepatology"},{"issue":"5","key":"pone.0316158.ref018","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jhep.2015.07.010","article-title":"Relationship of sitting time and physical activity with non-alcoholic fatty liver disease","volume":"63","author":"S Ryu","year":"2015","journal-title":"J Hepatol"},{"key":"pone.0316158.ref019","unstructured":"ARS Grand Est. Diab\u00e8te en Grand Est. Chiffres cl\u00e9s. https:\/\/www.grand-est.ars.sante.fr\/diabete-en-region-grand-est-chiffres-cles."},{"issue":"6","key":"pone.0316158.ref020","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"pone.0316158.ref021","unstructured":"Questionnaire Ricci et Gagnon.pdf https:\/\/www.obecentre.fr\/wp-content\/uploads\/2015\/12\/questionnaire-ricci-et-gagnon.pdf."},{"issue":"4","key":"pone.0316158.ref022","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jhep.2010.07.033","article-title":"Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy","volume":"54","author":"EA Tsochatzis","year":"2011","journal-title":"J Hepatol"},{"issue":"6","key":"pone.0316158.ref023","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"PJ Eddowes","year":"2019","journal-title":"Gastroenterology"},{"issue":"5","key":"pone.0316158.ref024","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis","volume":"66","author":"T Karlas","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"pone.0316158.ref025","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"M Eslam","year":"2020","journal-title":"J Hepatol"},{"issue":"7208","key":"pone.0316158.ref026","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/bmj.319.7208.508","article-title":"Methods in health service research. An introduction to bayesian methods in health technology assessment","volume":"319","author":"DJ Spiegelhalter","year":"1999","journal-title":"BMJ"},{"key":"pone.0316158.ref027","volume-title":"Bayesian approaches to clinical trials and health-care evaluation","author":"DJ Spiegelhalter","year":"2004"},{"issue":"12","key":"pone.0316158.ref028","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/aje\/153.12.1222","article-title":"Commentary: practical advantages of Bayesian analysis of epidemiologic data","volume":"153","author":"DB Dunson","year":"2001","journal-title":"Am J Epidemiol"},{"issue":"4","key":"pone.0316158.ref029","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"ZM Younossi","year":"2019","journal-title":"J Hepatol"},{"issue":"4","key":"pone.0316158.ref030","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"S Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"pone.0316158.ref031","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2337\/dc19-1071","article-title":"Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes","volume":"43","author":"F Bril","year":"2020","journal-title":"Diabetes Care"},{"issue":"8","key":"pone.0316158.ref032","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1136\/gutjnl-2015-309265","article-title":"Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study","volume":"65","author":"R Kwok","year":"2016","journal-title":"Gut"},{"issue":"8","key":"pone.0316158.ref033","first-page":"1396","article-title":"Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography","volume":"34","author":"L-L Lai","year":"2019","journal-title":"J Gastroenterol"},{"issue":"4","key":"pone.0316158.ref034","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3390\/jcm9041032","article-title":"Screening for liver fibrosis and steatosis in a large cohort of patients with type 2 diabetes using vibration controlled transient elastography and controlled attenuation parameter in a single-center real-life experience","volume":"9","author":"I Sporea","year":"2020","journal-title":"J Clin Med"},{"issue":"3","key":"pone.0316158.ref035","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/hep.32665","article-title":"Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD","volume":"77","author":"CM Canivet","year":"2023","journal-title":"Hepatology"},{"issue":"4","key":"pone.0316158.ref036","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1053\/j.gastro.2023.06.013","article-title":"AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review","volume":"165","author":"JJ Wattacheril","year":"2023","journal-title":"Gastroenterology"},{"issue":"5","key":"pone.0316158.ref037","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"ME Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"12","key":"pone.0316158.ref038","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1111\/liv.13481","article-title":"Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan","volume":"37","author":"D Roulot","year":"2017","journal-title":"Liver Int"},{"issue":"4","key":"pone.0316158.ref039","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/hep.31142","article-title":"Serial transient elastography examinations to monitor patients with type 2 diabetes: a prospective cohort study","volume":"72","author":"HW Lee","year":"2020","journal-title":"Hepatology"},{"issue":"6","key":"pone.0316158.ref040","doi-asserted-by":"crossref","first-page":"426","DOI":"10.4103\/sjg.sjg_73_22","article-title":"Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: evidence from the CORDIAL cohort study","volume":"28","author":"AA Alfadda","year":"2022","journal-title":"Saudi J Gastroenterol"},{"issue":"1","key":"pone.0316158.ref041","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cgh.2018.04.043","article-title":"Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease","volume":"17","author":"MS Siddiqui","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"pone.0316158.ref042","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.3390\/jcm12093336","article-title":"Smoking increases the risk of hepatocellular carcinoma and cardiovascular disease in patients with metabolic-associated fatty liver disease","volume":"12","author":"JJ Yoo","year":"2023","journal-title":"J Clin Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0316158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T18:26:43Z","timestamp":1738261603000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0316158"}},"subtitle":[],"editor":[{"given":"Anna","family":"Di Sessa","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0316158","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]}}}